GE Launches new Voluson E10 featuring world's first curved electronic 4D probe and next generation of HDlive
Barcelona, Spain September 15, 2014 - GE Healthcare announced today commercial availability in the U.S, Europe and Japan for its new Voluson E10 ultrasound system featuring the world's first curved matrix electronic 4D probe designed specifically for OB/GYN and the next generation version of its HDlive software.
September 11, 2014 (St. John's, NL): The Newfoundland and Labrador Centre for Health Information (the Centre) has partnered with GE Healthcare to install a province-wide Telepathology Network. The $2.5 million Telepathology Network, jointly funded by the Government of Newfoundland and Labrador and Canada Health Infoway, will give patients and pathologists across the province greater access to pathology services and support.
Wauwatosa, WI, September 3, 2014 --- GE Healthcare (NYSE: GE) today announced the FDA approval of SenoClaire*, GE's new breast tomosynthesis solution designed with a three-dimensional imaging technology. In collaboration with Massachusetts General Hospital, GE developed SenoClaire technology that uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a "step-and-shoot" method, removing the potential motion from the tube helping to reduce blur and increase image sharpness.
On the eve of the European Congress of Pathology in London, new research shows the pathologist's critical role in tackling cancer is not widely understood.
Chalfont St Giles, 29 August 2014 -- As the European Congress of Pathology begins this weekend in London, new research from GE Healthcare shows that many people do not understand the importance of the pathologist in the diagnosis and treatment of breast cancer1, the most common cancer in Europe, with more than 464,000 new cases diagnosed in 2012.2
MARLBOROUGH, Mass., Aug.
